Eli Lilly and Company (NYSE:LLY) Receives New Coverage from Analysts at Sanford C. Bernstein

Investment analysts at Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company (NYSE:LLY) in a note issued to investors on Thursday, MarketBeat reports. The firm set an “outperform” rating and a $1,100.00 price target on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 19.84% from the stock’s current price.

LLY has been the subject of several other reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Citigroup started coverage on Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target for the company. Guggenheim increased their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group increased their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research note on Monday, June 24th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $986.00.

Eli Lilly and Company Stock Up 0.1 %

NYSE LLY opened at $917.86 on Thursday. The business has a fifty day moving average price of $921.21 and a two-hundred day moving average price of $857.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a fifty-two week low of $547.61 and a fifty-two week high of $972.53. The stock has a market capitalization of $872.34 billion, a PE ratio of 135.18, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Equities analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

A number of large investors have recently bought and sold shares of LLY. Banque Cantonale Vaudoise grew its holdings in Eli Lilly and Company by 9.9% during the 1st quarter. Banque Cantonale Vaudoise now owns 26,503 shares of the company’s stock worth $20,617,000 after acquiring an additional 2,383 shares during the period. Conrad Siegel Investment Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the 1st quarter valued at about $231,000. Wedmont Private Capital grew its stake in shares of Eli Lilly and Company by 5.6% in the 1st quarter. Wedmont Private Capital now owns 11,825 shares of the company’s stock valued at $8,955,000 after buying an additional 627 shares during the period. Grandview Asset Management LLC grew its stake in shares of Eli Lilly and Company by 42.4% in the 1st quarter. Grandview Asset Management LLC now owns 763 shares of the company’s stock valued at $593,000 after buying an additional 227 shares during the period. Finally, Lantz Financial LLC grew its stake in shares of Eli Lilly and Company by 1.6% in the 1st quarter. Lantz Financial LLC now owns 1,220 shares of the company’s stock valued at $949,000 after buying an additional 19 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.